English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/180344
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorHernández-Álvarez, Noemies_ES
dc.contributor.authorPascasio, Juan Manueles_ES
dc.contributor.authorQuintero, Enriquees_ES
dc.contributor.authorFernández Vázquez, Inmaculadaes_ES
dc.contributor.authorGarcía-Eliz, Maríaes_ES
dc.contributor.authorRevilla Negro, Juan de laes_ES
dc.contributor.authorCrespo García, Javieres_ES
dc.contributor.authorHernández-Guerra, Manueles_ES
dc.date.accessioned2019-04-22T14:22:01Z-
dc.date.available2019-04-22T14:22:01Z-
dc.date.issued2017-
dc.identifier.citationBMJ Open Gastroenterology 4(1): e000115 (2017)es_ES
dc.identifier.urihttp://hdl.handle.net/10261/180344-
dc.descriptionHepatiC Registry-
dc.description.abstractBackground and aims] Rapid viral response (RVR) during antiviral treatment for hepatitis C virus (HCV) predicts sustained viral response (SVR). Recently, vitamin D levels have been associated with SVR. As sunlight is the most important source of vitamin D and shows seasonal variation, we evaluated the effect of season on viral kinetics during peginterferon/ribavirin-based therapy for HCV.es_ES
dc.description.abstract[Methods] Consecutive HCV patients treated with peginterferon/ribavirin and boceprevir/ telaprevir (June 2011–July 2014) were included. Patients were grouped according to season when therapy was initiated (Season A: May–October and Season B: November–April) depending on hours of daily sunlight. Multiple logistic regression analysis included factors known to influence SVR to treatment. The dependent variables were undetectable viral load (VL) or VL ≤15 UI/mL (VL ≤15) at weeks 4, 8 and 12, end of treatment and SVR.es_ES
dc.description.abstract[Results] The study included 930 patients (66.8% men; median 54 years) treated with telaprevir (n=537) or boceprevir, without (n=481) or with lead-in therapy of peginterferon/ribavirin. Baseline characteristics of patients in Season A (45.3%, n=421) and Season B groups were similar. Overall, a higher rate of RVR (23.5% vs 16.1%, p=0.005) and VL ≤15 (51.0% vs 38.6%, p≤0.001) was observed in patients starting treatment during Season A versus Season B. By logistic regression analysis, initiating treatment in Season A proved to be an independent predictor of RVR and VL ≤15.es_ES
dc.description.abstract[Conclusions] In our setting, seasonality affects viral kinetics in HCV genotype 1 patients treated with peginterferon/ribavirin-based therapy. Our findings support the hypothesis that vitamin D influences viral response to peginterferon/ribavirin-based therapy.es_ES
dc.language.isoenges_ES
dc.publisherBMJ Publishing Groupes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.titleEffect of season and sunlight on viral kinetics during hepatitis C virus therapyes_ES
dc.typeartículoes_ES
dc.identifier.doihttp://dx.doi.org/10.1136/bmjgast-2016-000115-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1136/bmjgast-2016-000115es_ES
dc.identifier.e-issn2054-4774-
dc.rights.licensehttp://creativecommons.org/licenses/by-nc/4.0/es_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
e000115.full.pdf987,33 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.